In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

The continuous glucose monitoring device allows patients to monitor blood sugar levels in real time. Read more at ...

DexCom has had a rough ride this year. The medical technology company is grappling with concerns about its slowing growth and allegations of faulty blood glucose monitors. However, DexCom is “already ...

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies ...

The GRACE trial suggests that real time continuous monitoring can reduce the risk of having a larger baby in women with ...

Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...

Automated insulin delivery systems — a continuous glucose monitor, insulin pump, and algorithm — enable athletes to manage ...

Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Some glucose monitor sensors from Abbott Diabetes Care have been recalled and patients have been urged to stop use immediately, according to a new alert from the Food and Drug Administration (FDA).

Automated insulin delivery systems can help pregnant women with type 1 diabetes manage their glucose during gestation.